{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:50:57Z","timestamp":1774129857039,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"City of Dublin Skin and Cancer Hospital Charity"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hidradenitis suppurativa (HS) is a chronic condition with a significant psychological and physical burden but a paucity of effective treatments. Early intervention with adalimumab improves disease outcomes. Two previous studies in Denmark and Northern Ireland have identified a time of 8.2 and 2.9\u2005years, respectively, from first HS systemic\/dermatology consultation to commencing a biologic. We aimed to evaluate the time from disease onset and from first specialty HS clinic review to the initiation of biologic therapy. We retrospectively reviewed 34 patients on biologic treatment for HS. The mean diagnostic delay was 12.4\u2005years. The mean time from disease onset to biologic initiation was 14.8\u2005years. Prior to a biologic, patients received a median of 3.3 treatments from the specialty HS clinic. The median time to biologic from first presentation at the specialty HS clinic was 1\u2005year. This is shorter than the therapeutic delay reported in dermatology clinics in Denmark and Northern Ireland, providing evidence on the importance of specialized HS treatment. However, to make an impact with specialized HS care and earlier biologic initiation, diagnostic delay needs to be reduced.<\/jats:p>","DOI":"10.1093\/ced\/llad191","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T14:47:05Z","timestamp":1685544425000},"page":"1149-1151","source":"Crossref","is-referenced-by-count":5,"title":["Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-3462","authenticated-orcid":false,"given":"Niamh","family":"Kearney","sequence":"first","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital Dublin , Dublin , Ireland"},{"name":"School of Medicine, University College Dublin , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"O\u2019Donohoe","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital Dublin , Dublin , Ireland"},{"name":"School of Medicine, University College Dublin , Dublin , Ireland"},{"name":"Charles Institute of Dermatology, University College Dublin , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital Dublin , Dublin , Ireland"},{"name":"School of Medicine, University College Dublin , Dublin , Ireland"},{"name":"Charles Institute of Dermatology, University College Dublin , Dublin , Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2023091916465422600_llad191-B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023091916465422600_llad191-B2","doi-asserted-by":"crossref","first-page":"9716","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory drugs in the treatment of hidradenitis suppurativa \u2013 possibilities and limitations","volume":"23","author":"\u015awierczewska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2023091916465422600_llad191-B3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2023091916465422600_llad191-B4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2023091916465422600_llad191-B5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023091916465422600_llad191-B6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjd.21673","article-title":"The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study","volume":"187","author":"Ring","year":"2022","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"2023091916465422600_llad191-B7","first-page":"21","article-title":"Patient journey from disease onset to commencing a biologic in hidradenitis suppurativa is complicated by diagnostic and therapeutic delay","volume":"91","author":"Kearney","year":"2022","journal-title":"Ulster Med J"},{"key":"2023091916465422600_llad191-B8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023091916465422600_llad191-B9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project","volume":"187","author":"Midgette","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023091916465422600_llad191-B10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1525-1497.1999.08168.x","article-title":"Knowledge, patterns of care, and outcomes of care for generalists and specialists","volume":"14","author":"Harrold","year":"1999","journal-title":"J Gen Intern Med"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad191\/50913473\/llad191.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1149\/51685156\/llad191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1149\/51685156\/llad191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T17:07:18Z","timestamp":1695143238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/10\/1149\/7187150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad191","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,5,31]]}}}